PFE - Novo Nordisk sees launching new obesity drugs before Wegovy patent expires
2024-03-08 11:25:31 ET
More on Novo Nordisk
- Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
- Novo Nordisk, A Very Healthy Pharma Stalwart
- Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
- Novo Nordisk expects Wegovy approval in China this year: report
- Biggest stock movers today: NYCB, NVO, VSCO, BIG, and more